AarogyaAI, a Delhi, India-based Healthtech startup raised $700,000 (Rs 5.2 crore approx) as a part of its seed funding round from Info Edge (India)-backed Redstart Labs and Avaana Capital (Seed Program).
Existing investors Entrepreneur First (EF) and First In Ventures also participated in the round.
The funding will primarily be used for Research & Development (R&D), team expansion, validation, and pilot deployments.
Company: AarogyaAI Innovations Private Limited
Round: Seed Round
Funding Month: January 2022
Lead Investors: Redstart Labs and Avaana Capital
Additional Investors: Entrepreneur First (EF) and First In Ventures
Company Website: https://aarogya.ai/
Software Category: AI-enabled SaaS that diagnoses drug-resistant tuberculosis
About the Company: Founded in 2019 by scientists Praapti Jayaswal and Avlokita Tiwari, the startup has built a SaaS (software-as-a-service) platform where the DNA sequence from the bacteria, also known as genome sequencing, infecting a patient can be uploaded, which is then analyzed using a machine learning (ML) algorithm and AI to generate a report showing the patient’s comprehensive drug susceptibility status. Operating on a B2B2C (business-business-to-consumer) model, AarogyaAI’s customers include diagnostic labs and hospitals, and pharmaceuticals in the long run as it accumulates more data to provide insights about antibiotic development. The startup is also focussing on building dashboard analytics that showcases disease demographics, the spread of drug resistance, and the patterns of emerging drug resistance.